Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma

Documenti analoghi

• Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
  di: Bodiford, Andrew, et al.
  Pubblicazione: (2014)
• Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review
  di: Sawas, Ahmed, et al.
  Pubblicazione: (2015)
• Treatment approaches in relapsed or refractory peripheral T-cell lymphomas
  di: Foster, Cheryl, et al.
  Pubblicazione: (2020)
• Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
  di: O'Connor, Owen A., et al.
  Pubblicazione: (2015)
• Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas
  di: Allen, Pamela B, et al.
  Pubblicazione: (2018)